Yael Cohen, MD, Tel-Aviv Sourasky Medical center, Tel-Aviv, Israel, discusses the use of single-cell approaches in predicting response to treatment and discovering the mechanisms of resistance to various drug combinations in multiple myeloma. Dr Cohen explains that single-cell RNA sequencing (scRNA-seq) can provide information on the transcriptomic changes associated with drug resistance, and highlights the potential use of this technology in the clinic to choose and sequence treatments. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.